ADUS vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ADUS exhibits mixed financial health with a Piotroski F-Score of 4/9, indicating a weak to stable foundation, and no Altman Z-Score available, which limits distress risk assessment. The stock trades at $101.35, below its intrinsic value of $153.99 and Graham Number of $83.83, suggesting potential undervaluation on a defensive basis. However, strong revenue and earnings growth (25.6% and 52.1% YoY) are tempered by bearish insider activity and a lack of dividend. Analysts maintain a 'buy' recommendation with a target of $140.23, reflecting optimism in future performance.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ADUS vs LLY: Head-to-Head Comparison
This page compares Addus HomeCare Corporation (ADUS) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.